NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Source: PRnewswire
Preclinical Findings on AEX-2: NLS Pharmaceutics and Aexon Labs announced promising preclinical results for AEX-2, a non-sulfonamide dual orexin receptor agonist, showing its potential to enhance wakefulness, preserve REM sleep, and reduce cataplexy in narcolepsy, while also targeting neuroinflammation and metabolic disorders.
Future Development Plans: The companies plan to advance AEX-2 and AEX-41 into IND-enabling studies in 2025, with first-in-human clinical trials expected by 2026, aiming to broaden their applications beyond sleep disorders to include neurodegenerative diseases and diabetes-associated neurological conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
